Pharmaceuticals
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...
2026-08-31 20:38
31
SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring
MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with...
2026-08-31 12:17
24
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
* Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant and have received at lea...
2026-08-31 09:00
4
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and 60 mg) over 72...
2026-08-30 18:15
1
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the ...
2026-08-28 19:30
2029
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
* Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization * DUPAC, one of the DualityBio's four proprietary ADC technology platforms, comprises...
2026-08-28 12:20
5
Kazia Therapeutics Limited Announces Proposed Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that...
2026-08-28 05:14
4
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively No Treatment-Related Serious Adverse Events Observed SYDNEY, ...
2026-08-28 04:01
3691
Global genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer care
MELBOURNE, Australia, Aug. 28, 2026 /PRNewswire/ -- Global multi-omics leader Novogene is establishing its first Australian laboratory at Cabrini Health, bringing advanced genomic capabilities closer to Australian patients and researchers, reducing the wait for genomic test results that can infor...
2026-08-28 04:00
4016
Flexsys Narrows 6PPD Replacement to Two Final Molecules and Enters Cooperative Research and Development Agreement with U.S. Geological Survey for Independent Toxicity Testing
These two steps bring a 6PPD replacement closer to market, as federal scientists will conduct extensive aquatic toxicity testing - a critical step toward final molecule selection and commercialization. AKRON, Ohio, Aug. 27, 2026 /PRNewswire/ -- Flexsys, a global leader in material science and ad...
2026-08-27 23:00
3063
Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion
Highlights: * Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%; * Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion...
2026-08-27 19:27
AsiaPay Partners with Generika Drugstore to Launch a Convenient and Secure Digital Payment Solution, Enhancing Customer Payment Experience in The Philippines
MANILA, Philippines, Aug. 27, 2026 /PRNewswire/ -- AsiaPay, a leading digital payment service provider and technology company in Asia, has partnered with Generika Drugstore, the country's premier generic pharma retail chain and part of AC Health, the healthcare arm of the Ayala Group, to signific...
2026-08-27 17:31
2360
Sunway Medical Centre Penang Receives Dual Honours at the Asia Pacific Enterprise Awards (APEA) 2026 Regional Edition for Healthcare Excellence and Brand Leadership
SINGAPORE, Aug. 27, 2026 /PRNewswire/ -- Sunway Medical Centre Penang (SMCP) has been honoured with the Corporate Excellence and Inspirational Brand awards at the Asia Pacific Enterprise Awards (APEA) 2026 Regional Edition by Enterprise Asia, recognising its strong growth trajectory as a leading ...
2026-08-27 16:27
8
Countdown to BIOHK2026: World-Class Biotech Convention Prepares to Host Global Pavilions, Multi-Track Forums, and Signature Executive Networking
HONG KONG, Aug. 27, 2026 /PRNewswire/ -- As a premier global landmark in
biotech, BIOHK2026 convenes international biotech hubs, cross-disciplinary
industry forums, and high-impact networking events to accelerate cross-border
partnerships in Hong Kong.
2026-08-27 12:06
2429
Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta
BUENOS AIRES, Argentina, Aug. 27, 2026 /PRNewswire/ -- Biosidus, an Argentine biotechnology company with more than four decades of experience in the development and manufacturing of biosimilar medicines, announced that its new bioreactor plant is now operational, increasing the company's biologic...
2026-08-27 05:00
1
DarwinHealth Introduces Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision Oncology
New paradigm integrates single-cell transcriptomics, regulatory network inference, and AI to decode—and therapeutically target—the multiple, co-existing cancer cell states that drive resistance in pancreatic cancer, glioblastoma, and other lethal malignancies NEW YORK, Aug. 26, 2026 /PRNewswire/...
2026-08-26 20:38
2323
Alebund Pharmaceuticals Announces 2026 Interim Results
SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period...
2026-08-26 18:59
2536
HaemaLogiX Announces Major Milestone with First Patient Successfully Dosed with KMCAR™ T-Cell
KEY POINTS * First patient safely dosed in Phase 1 KOALA trial evaluating KMCAR™ T-cell therapy in patients with relapsed/refractory kappa-restricted multiple myeloma * Patient was monitored after initial dose to assess response and side-effects, with the treatment seen as well tolerated, an...
2026-08-26 08:00
830
Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
EAST RUTHERFORD, N.J., Aug. 25, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the successful completion of three Pre-Approval Inspections (PAIs) at its High Point, North Carolina facility by the U.S. Food and Drug Admini...
2026-08-25 18:00
617
ICP DAS-BMP Brings Advanced Medical TPU Portfolio to Medical Manufacturing Asia 2026
HSINCHU, Aug. 25, 2026 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), will exhibit at Medical Manufacturing Asia 2026, taking place September 9–11 at the Marina Bay Sands Expo & Convention Centre in Sin...
2026-08-25 09:15
916
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 314 media titles]
2026-08-27 10:25
Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 299 media titles]
2026-08-25 10:00Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
[Picked up by 291 media titles]
2026-08-25 07:00
ViewSonic Launches XG2738-2K-OLED Gaming Monitor with QD-OLED Technology and OLED Care
[Picked up by 288 media titles]
2026-08-27 10:30
Most Read
OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
2026-08-24 15:42
19979
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
2026-08-24 10:00
19851
Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
2026-08-25 07:00
17810
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
13462